Spots Global Cancer Trial Database for bone marrow
Every month we try and update this database with for bone marrow cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Granulocyte Colony Stimulating Factor (G-CSF) for Bone Marrow Transplant (BMT) | NCT00231309 | Hematologic Dis... Hematologic Mal... | Granulocyte Col... | - 55 Years | Emory University | |
| Quantitative MRI of Bone Marrow in Patients With Acute Lymphoblastic Leukemia | NCT04767165 | Acute Leukemia | MRI | 6 Years - 18 Years | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| Characteristics of Mast Cells in Mastocytosis | NCT00001356 | Mastocytosis | - | National Institutes of Health Clinical Center (CC) | ||
| Cancer in Inherited Bone Marrow Failure Syndromes | NCT00027274 | Diamond Blackfa... Dyskeratosis Co... Fanconi Anemia Shwachman Diamo... Inherited Bone ... | - | National Institutes of Health Clinical Center (CC) | ||
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | NCT01183429 | Neuroblastoma | 3F8 and 13-cis-... | 18 Months - | Memorial Sloan Kettering Cancer Center | |
| Shwachman Diamond Syndrome Registry and Study | NCT06056908 | Shwachman-Diamo... Shwachman-Diamo... | - | Boston Children's Hospital | ||
| An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | NCT00544440 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis | NCT02057289 | Immunocompromis... Bone Marrow Tra... Cancer | Micafungin | 6 Months - 10 Years | Children's Hospital Medical Center, Cincinnati | |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | NCT01242774 | Acute Myeloid L... | Panobinostat | 18 Years - 65 Years | Novartis | |
| Hematotoxic Effects of Particulate Exposure | NCT00015483 | Cancer | 18 Years - 55 Years | National Institute of Environmental Health Sciences (NIEHS) | ||
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | NCT01183429 | Neuroblastoma | 3F8 and 13-cis-... | 18 Months - | Memorial Sloan Kettering Cancer Center | |
| Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic Irradiation | NCT04626466 | Prostate Carcin... Rectum Carcinom... Anal Canal Carc... Endometrium Car... Cervix Carcinom... Radiotherapy Vaginal Cancer | Biological inve... | 18 Years - 79 Years | Institut de cancérologie Strasbourg Europe | |
| Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | NCT01463670 | Multiple Myelom... | lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Gene Therapy in HIV-Positive Patients With Non-Hodgkin's Lymphoma | NCT00002221 | Lymphoma, Non-H... HIV Infections | Peripheral bloo... | 18 Years - 60 Years | NIH AIDS Clinical Trials Information Service | |
| Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma | NCT01757626 | Neuroblastoma | Hu3F8 With GM-C... Hu3F8 With GM-C... | 1 Year - | Memorial Sloan Kettering Cancer Center | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma | NCT00087867 | Multiple Myelom... | SCIO-469 SCIO-469 and bo... | 18 Years - | Scios, Inc. | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| The Effect of Music Therapy on Comfort, Pain and Anxiety | NCT05895357 | Bone Marrow Dis... Hematological M... | Musictherapy | 18 Years - 100 Years | Izmir Bakircay University | |
| Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases | NCT00910728 | Primary Myelofi... Post-Polycythae... Essential Throm... | AZD1480 | 25 Years - 99 Years | AstraZeneca | |
| Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | NCT00620633 | Leukemia Myelodysplastic... | WT1-sensitized ... | - | Memorial Sloan Kettering Cancer Center | |
| Erlotinib Study for Myelodysplastic Syndrome (MDS) | NCT00977548 | Myelodysplastic... | Erlotinib | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers | NCT01717391 | Uterine Cervica... Endometrial Neo... Anus Neoplasms Rectal Neoplasm... Prostatic Neopl... | fluorothymidine... | 18 Years - | University of Iowa | |
| Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00519090 | Myelogenous Leu... | Imatinib Nilotinib (AMN1... | 18 Years - | Novartis | |
| An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma | NCT00544440 | Prostate Neopla... | Abiraterone ace... Prednisone | 18 Years - | Janssen Research & Development, LLC | |
| Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement | NCT00992758 | Lymphoma, Non-H... | Iodine-131 Anti... | 18 Years - | GlaxoSmithKline | |
| Use of Stem Cells Cultured on a Scaffold for the Treatment of Aneurysmal Bone Cysts (ABC) | NCT03066245 | Aneurysmal Bone... | MSC-PLGA | 4 Years - 28 Years | University of Jordan | |
| Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation | NCT00620633 | Leukemia Myelodysplastic... | WT1-sensitized ... | - | Memorial Sloan Kettering Cancer Center | |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer | NCT04331067 | Triple Negative... | Paclitaxel Carboplatin Nivolumab Cabiralizumab Tumor biopsy Bone marrow Blood draw | 18 Years - | Washington University School of Medicine | |
| Cause and Natural Course of Pediatric-Onset Mastocytosis | NCT00050193 | Mastocytosis | - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | NCT00750815 | Multiple Myelom... | Cyclophosphamid... Bortezomib; Peg... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | NCT03839446 | Acute Myeloid L... | mitoxantrone + ... | 18 Years - 75 Years | University of Pittsburgh | |
| Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | NCT01463670 | Multiple Myelom... | lenalidomide | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis | NCT02057289 | Immunocompromis... Bone Marrow Tra... Cancer | Micafungin | 6 Months - 10 Years | Children's Hospital Medical Center, Cincinnati | |
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| Study of Factors Regulating Mast Cell Proliferation | NCT00044122 | Mastocytosis Monoclonal Bone Marrow Tryptase | 1 Day - 80 Years | National Institutes of Health Clinical Center (CC) | ||
| Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission | NCT04914676 | Acute Myeloid L... | Cytarabine Cytarabine | 61 Years - 99 Years | University of Florida | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment | NCT04333108 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science | |
| A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE | NCT04258683 | Multiple Myelom... | Pembrolizumab | 18 Years - | Canadian Myeloma Research Group | |
| Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | NCT03770273 | Indolent System... | sarilumab Placebo | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Constitution of a Biological Cohort Following Bone Marrow Sampling From MDS or AML Patients and Age-matched Healthy Donors | NCT03233074 | Myelodysplastic... Acute Myeloid L... Cardio-vascular... | Bone marrow ana... | 50 Years - 80 Years | Centre Hospitalier Universitaire de Saint Etienne | |
| Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT | NCT01012492 | AML ALL Undifferentiate... Biphenotypic Le... Refractory Anem... Refractory Anem... Refractory Cyto... Ref. Cytopenia ... Refractory Anem... Refractory Anem... Myelodysplastic... MDS Associated ... | Abatacept | 12 Years - | Boston Children's Hospital | |
| INCB018424 in Patients With Advanced Hematologic Malignancies | NCT00674479 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Chronic Myeloge... | INCB018424 | 18 Years - | M.D. Anderson Cancer Center | |
| Cause and Natural Course of Pediatric-Onset Mastocytosis | NCT00050193 | Mastocytosis | - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) | NCT04155580 | Acute Myeloid L... | ASTX660 ASTX727 | 18 Years - | Astex Pharmaceuticals, Inc. | |
| The Effect of Music Therapy on Comfort, Pain and Anxiety | NCT05895357 | Bone Marrow Dis... Hematological M... | Musictherapy | 18 Years - 100 Years | Izmir Bakircay University | |
| A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis | NCT00931762 | Primary Myelofi... Post-Polycythem... Post-Essential ... | Panobinostat | 18 Years - | Novartis | |
| The Expression of Antigens in Bone Marrow Samples From Volunteering Donors. | NCT00706199 | Cancer | Bone marrow asp... | 18 Years - | GlaxoSmithKline | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| Hypofractionation (Radiation) Trial for Multiple Myeloma | NCT06270888 | Multiple Myelom... | Radiation | 18 Years - | University of Chicago | |
| 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | NCT01183429 | Neuroblastoma | 3F8 and 13-cis-... | 18 Months - | Memorial Sloan Kettering Cancer Center | |
| Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS | NCT05593185 | Acute Myeloid L... Myelodysplastic... | Galinpepimut-S | 18 Years - | Sellas Life Sciences Group | |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | NCT03114865 | Acute Lymphobla... B-cell Non Hodg... Pre B-Cell Acut... | Blinatumomab 9u... Blinatumomab 28... Blinatumomab Dexamethasone | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS) | NCT01034657 | Myelodysplastic... | LBH589 Epoetin Alfa | 18 Years - | Novartis | |
| Thiotepa-Clofarabine-Busulfan With Allogeneic Stem Cell Transplant for High Risk Malignancies | NCT00857389 | Stem Cell Trans... Leukemia Lymphoma | Thiotepa Clofarabine Busulfan Allogeneic Stem... Thymoglobulin (... G-CSF (Filgrast... Tacrolimus Methotrexate Cyclophosphamid... Mesna | - 60 Years | M.D. Anderson Cancer Center | |
| A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) | NCT00471497 | Myelogenous Leu... | nilotinib imatinib | 18 Years - | Novartis | |
| Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis | NCT00814073 | Indolent System... | Masitinib Placebo Best Supportive... | 18 Years - 75 Years | AB Science |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
